- Home
- CSTL vs RIGL Comparison
CSTL vs RIGL Comparison
Compare CSTL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- RIGL
- Stock Information
- Founded
- CSTL 2007
- RIGL 1996
- Country
- CSTL United States
- RIGL United States
- Employees
- CSTL N/A
- RIGL N/A
- Industry
- CSTL Medical Specialities
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- RIGL Health Care
- Exchange
- CSTL Nasdaq
- RIGL Nasdaq
- Market Cap
- CSTL 661.7M
- RIGL 537.6M
- IPO Year
- CSTL 2019
- RIGL 2000
- Fundamental
- Price
- CSTL $33.85
- RIGL $37.26
- Analyst Decision
- CSTL Strong Buy
- RIGL Buy
- Analyst Count
- CSTL 6
- RIGL 6
- Target Price
- CSTL $38.67
- RIGL $39.83
- AVG Volume (30 Days)
- CSTL 391.5K
- RIGL 549.8K
- Earning Date
- CSTL 11-03-2025
- RIGL 11-04-2025
- Dividend Yield
- CSTL N/A
- RIGL N/A
- EPS Growth
- CSTL N/A
- RIGL 2698.26
- EPS
- CSTL N/A
- RIGL 6.20
- Revenue
- CSTL $343,530,000.00
- RIGL $282,076,000.00
- Revenue This Year
- CSTL N/A
- RIGL $59.93
- Revenue Next Year
- CSTL N/A
- RIGL N/A
- P/E Ratio
- CSTL N/A
- RIGL $6.11
- Revenue Growth
- CSTL 10.15
- RIGL 79.13
- 52 Week Low
- CSTL $14.59
- RIGL $13.91
- 52 Week High
- CSTL $35.84
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- CSTL 85.44
- RIGL 67.14
- Support Level
- CSTL $23.31
- RIGL $28.08
- Resistance Level
- CSTL $34.36
- RIGL $39.56
- Average True Range (ATR)
- CSTL 1.46
- RIGL 1.98
- MACD
- CSTL 1.10
- RIGL 0.96
- Stochastic Oscillator
- CSTL 95.87
- RIGL 81.29
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.